BioSpace News Archive

Data from study on Tumor Treating Fields in combination with anti-PD-1 therapy published in Cancer Immunology, Immunotherapy

Phesi, a data-driven provider of premier integrated clinical development products and services, today announced that the company has filed a new patent [U.S. Serial No. 62/986,746] that enables its systems to synthesize global patient data and assess baseline patient characteristics for clinical trial protocols

Tetraphase Pharmaceuticals, Inc.today reported financial results for the fourth quarter and year ended December 31, 2019.

X4 Pharmaceuticals, Inc. today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2019

The biopharma successfully produced Virus-Like Particles (VLP) of the coronavirus in just 20 days using proprietary plant-based technology

Agenus Inc.today announced that the U.S. Food and Drug Administration (FDA) has granted Agenus Fast Track designation for investigation of balstilimab [PD-1] in combination with zalifrelimab [CTLA-4]

EXUMA Biotech Corp. (formerly F1 Oncology), a clinical-stage biotechnology company discovering and developing CAR-T therapies for solid and liquid tumors, today announced a $19M Series B round of financing that includes new investments by MSD Partners and F1 BioVentures, as well as conversion of notes held by individual investors.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced the retirement of Professor John L. Gainer, Ph.D., the company’s chief science officer.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced it has settled the previously disclosed class-action lawsuit against it pending in the U.S. District Court for the District of New Jersey.

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today reported financial results for the fourth quarter and year ended December 31, 2019.